Replies to post #239045 on Biotech Values

[floblu14]

Fresh off IPO, ‘biofacturing’ company Zymergen’s stock plunges about 70% after some really bad news
Last Updated: Aug. 3, 2021 at 6:16 p.m. ET

Less than four months after going public, Zymergen announces that its sole current product is struggling, a major target market may not pan out, and the CEO is gone; more than two-thirds of $3 billion-plus valuation disappears.

Read more:
https://www.marketwatch.com/story/fresh-off-ipo-biofacturing-company-zymergens-stock-plunges-more-than-70-after-some-really-bad-news-11628025855

[jbog]

ZY went public only three months ago

No question the Company, it's Bankers and the Book Runners should be liable in this transaction.

[DewDiligence]

DNA acquires ZY for $2.94/sh* in stock—a 47% premium to Friday’s close:

https://www.prnewswire.com/news-releases/ginkgo-to-acquire-zymergen-301592281.html

The nominal deal value is $300M.

ZY is a basket case (#msg-165257288), so this is a good deal for shareholder, IMO.

*Based on 7/22/25 closing price.